Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis. (Q39129228)
Jump to navigation
Jump to search
scientific article published on 3 November 2016
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis. |
scientific article published on 3 November 2016 |
Statements
Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis (English)
Mark S Freedman
Aaron E Miller
Catherine Dive-Pouletty
Steven Hass
Karthinathan Thangavelu